GSK Lynavoy CHMP: First PBC Itch Drug for EU

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on July 23, 2026 recommending marketing authorization for Lynavoy (linerixibat), GSK’s oral ileal bile acid transporter (IBAT) inhibitor, for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC). Lynavoy is the first medicine to receive a CHMP positive opinion for this indication in the EU.

The EU regulatory step

The CHMP opinion is the scientific green light; European Commission approval typically follows within 67 days. The EU decision is a regulatory catch-up: the FDA approved Lynavoy on March 19, 2026 based on the GLISTEN Phase 3 trial, making it the first drug approved in the US specifically for cholestatic pruritus in PBC. GSK has since signed a licensing deal under which Alfasigma S.p.A. will acquire worldwide rights to develop, manufacture, and commercialize linerixibat, subject to regulatory clearances.

GSK closed at $51.35 on July 23. A niche rare disease drug does not move a large pharma stock meaningfully, but Lynavoy adds to GSK’s specialty portfolio and validates the IBAT inhibitor class.

The clinical evidence

The GLISTEN Phase 3 trial met both primary and key secondary endpoints, demonstrating significant, rapid (at Week 2) and sustained (over 24 weeks) improvements in cholestatic pruritus and itch-related sleep interference versus placebo. The trial enrolled patients with PBC who were already on ursodeoxycholic acid, the standard-of-care disease-modifying therapy, but still experiencing debilitating itch.

Linerixibat works by blocking the IBAT in the ileum, the final segment of the small intestine where bile acids are normally reabsorbed and recycled back to the liver. By interrupting that recycling, linerixibat reduces the bile acid pool that drives the intense, often treatment-refractory itching that up to 89% of PBC patients experience. The drug does not slow the underlying bile duct destruction, but it addresses the symptom patients consistently rank as the most distressing part of their disease.

Why this is a quality-of-life story

PBC is a rare autoimmune disease that gradually destroys the bile ducts in the liver. Patients can live with the disease for years, but the cholestatic pruritus it causes is an internal itch that does not respond to antihistamines. Severe cases drive sleep deprivation, depression, and in some patients, suicidal ideation. Liver transplant has been the only option for refractory itch in the absence of liver failure.

Before Lynavoy, no approved drug specifically targeted cholestatic pruritus in PBC. The IBAT inhibitor class also includes Bylvay (odevixibat, Ipsen) and Livdelzi (seladelpar, Gilead); Iqirvo (elafibranor, Ipsen) is a dual PPAR agonist, not an IBAT inhibitor. All are approved for PBC but without a specific pruritus claim. Linerixibat is the first to win a dedicated itch indication. The IBAT class has shown divergent outcomes across cholestatic diseases, as seen in the Ipsen Bylvay biliary atresia Phase 3 miss, where the same mechanism failed to improve native liver survival in pediatric biliary atresia.

What to watch next

The Alfasigma deal closing. The licensing agreement is subject to regulatory clearances including Hart-Scott-Rodino review in the US. If the deal closes, Linavoy becomes Alfasigma’s commercial asset and GSK exits the franchise. Watch for closing in Q3 2026, and for whether Alfasigma pursues label expansions into other cholestatic conditions.

Source: GSK press release | EMA CHMP meeting highlights, July 2026

What It Means for the Trade

For GSK the stock calculus is simple: at $51.35 with a $100 billion-plus market cap, a niche PBC itch drug is a rounding error, and the market correctly ignored the CHMP opinion. The real transaction is the Alfasigma out-license — GSK monetizing a symptom-relief asset rather than carrying a specialty launch inside a pipeline built for bigger bets. If the deal closes in Q3 2026, GSK exits with cash and the IBAT class validation; Alfasigma inherits the first dedicated pruritus claim in PBC on both sides of the Atlantic. The tradable angle is class-level: the CHMP positive opinion, following the March 2026 FDA approval on GLISTEN, makes linerixibat the only IBAT inhibitor with a specific cholestatic-pruritus indication in both the US and EU — a differentiation Ipsen’s Bylvay and the PPAR agents lack, even as those drugs hold broader PBC labels. For traders playing the IBAT space, that distinction is the whole competitive map.

Mechanism and Market Context

Cholestatic pruritus is a bile-acid problem, but not only a bile-acid problem: pruritogens accumulate when bile flow fails, and interrupting the enterohepatic recycling loop at the ileal transporter lowers the pool driving the itch signal. Linerixibat acts locally in the gut rather than systemically, which is why GLISTEN could show rapid Week-2 relief sustained over 24 weeks in patients already on ursodeoxycholic acid — the population where the disease-modifying backbone is in place but the itch persists anyway. The GLISTEN endpoints (pruritus plus itch-related sleep interference) map directly onto what patients rank as most distressing.

Risks and What Could Go Wrong

1. The Alfasigma closing depends on HSR and other regulatory clearances; a delay or unwind would return launch economics to GSK’s lap.
2. Symptom-only labels cap pricing — linerixibat does not slow bile duct destruction, and payers treat quality-of-life drugs differently from disease-modifiers.
3. PPAR-class competitors (Iqirvo, Livdelzi) hold broader PBC labels and could bundle itch benefit into their positioning.
4. The biliary atresia class failure shows IBAT efficacy does not generalize across cholestatic diseases — expansion bets should be discounted accordingly.